PubMed HealthSearch

Biomedical subjects

Xin Ma

Publications and source records attributed to Xin Ma.

4 recordsLinked to original sources

Isolation and Characterization of Botulinum Neurotoxin-Producing Clostridium caccae from Meat and Soil - China, 1990-2025.

WHAT IS KNOWN ABOUT THIS TOPIC?: Botulinum neurotoxin (BoNT)-producing clostridia are categorized into six physiologically and phylogenetically distinct groups (Groups I-VI). Increasing genomic evidence indicates that bont genes are distributed across multiple clostridial lineages, highlighting the taxonomic complexity of BoNT-producing clostridia. Clostridium caccae (C. caccae), first described in 2020 from human stool, was originally described as a strain lacking the bont gene; however, its association with BoNT production has not been previously recognized. WHAT IS ADDED BY THIS REPORT?: Six isolates originally identified as Group II C. botulinum in China were assigned to C. caccae based on the average nucleotide identity (ANI) analysis. In addition, 140 publicly available genomes of C. caccae were analyzed. Among the 146 C. caccae strains, 63% carried bont genes (subtypes B4, E9, E12, and F6), with geographical distribution patterns differing by subtype. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: A subset of Group II C. botulinum strains should be considered as C. caccae, indicating that this species represents a previously under-recognized reservoir of multiple BoNT subtypes. To our knowledge, this is the first study to link BoNT-producing C. caccae to both soil contamination and human botulism, highlighting that BoNT-producing C. caccae may be an under-recognized contributor to the risk of botulism.

Botulinum neurotoxin

Factors Associated With Accelerated Fracture Healing in Patients With Traumatic Brain Injury and Extremity Comminuted Fractures: A Retrospective Case-Control Study.

OBJECTIVE: Although traumatic brain injury (TBI) has been clinically associated with accelerated bone healing, the factors that determine which patients experience this phenomenon remain poorly defined, and previous findings are conflicting. This study aimed to investigate the clinical factors associated with accelerated fracture healing in patients with TBI combined with comminuted fractures of the limbs, so as to provide an evidence-based foundation for elucidating the clinical phenomenon of TBI-promoted fracture healing. METHODS: A retrospective case-control study design was employed. Patients between January 2020 and April 2024 with concurrent diagnoses of TBI and comminuted fractures were included. Based on radiographic findings and RUST/mRUST scores, patients were divided into an accelerated healing group (AHG) and a normal/delayed healing group (NDHG). Clinical data including demographics (age, sex, BMI), TBI characteristics (injury site, GCS score), admission laboratory indices (blood count, coagulation function, inflammatory markers), and fracture site/local soft tissue conditions, as well as functional outcomes assessed by the Short Musculoskeletal Function Assessment (SMFA) questionnaire at final follow-up were collected. Univariate analysis and multivariate logistic regression analysis were used to identify independent factors influencing accelerated fracture healing. Receiver operating characteristic (ROC) curves were plotted to evaluate their predictive value. RESULTS: A total of 119 patients were included, with 69 in the AHG and 50 in the NDHG. Significant differences were observed between the two groups in terms of age, BMI, GCS score, and platelet count (p&#x2009;<&#x2009;0.05). Univariate analysis showed that age, BMI, GCS score, red blood cell count, and platelet count were associated with accelerated fracture healing (p&#x2009;<&#x2009;0.20). Multivariate logistic regression analysis indicated that younger age (OR&#x2009;=&#x2009;0.875, 95% CI: 0.821-0.934) and lower GCS score (indicating more severe TBI; OR&#x2009;=&#x2009;0.490, 95% CI: 0.339-0.707) were independent predictors of accelerated fracture healing. ROC curve analysis showed that the area under the curve (AUC) for age and GCS score in predicting accelerated healing were 0.893 and 0.851, respectively. CONCLUSIONS: In patients with TBI combined with comminuted fractures, younger age and greater TBI severity (lower GCS score) are independent predictors of accelerated fracture healing. These findings assist clinicians in the early identification of patients with high healing potential to optimize treatment strategies, facilitate the early identification of high-risk patients, and provide clinical clues for further exploration of the molecular mechanisms underlying neurohumoral regulation of bone regeneration.

Humans

Efficient and precise programmable DNA knock-in without double-strand breaks.

Programmable gene knock-in holds substantial promise for treating genetic diseases and advancing cell therapies. However, achieving precise and efficient kilobase-scale DNA fragment integration remains challenging1,2. Here we report CRISPR kilobase-scale nickase-targeting (KNIT) editing for efficient, precise and programmable kilobase-scale DNA insertion without double-strand DNA cleavage, which is enabled through the coupling of a Cas9 nickase with a DNA donor recruiting system. KNIT editing facilitates programmable integration of DNA fragments from 0.7&#x2009;kb to more than 10&#x2009;kb and is effective across genomic&#xa0;loci and cell types. It achieves up to 89% efficiency&#xa0;and&#xa0;markedly reduces unintended insertion-deletion mutation (indels) rates, translocations and off-target editing. The system supports repeated insertion editing and multiloci gene knock-in with minimal translocations. Its enhanced version, KNIT editor&#x2009;2, further improves efficiency via a single transfection. Moreover, in mutant cells with a pathological mutation, KNIT editing restores normal gene expression by inserting a therapeutic gene into a safe harbour locus or its native locus. Notably, KNIT editing enables non-viral and programmable chimeric antigen receptor T cell&#xa0;(CAR-T&#x2009;cell) engineering without double-strand breaks and with clinically relevant efficiencies. Moreover, the engineered CAR-T&#x2009;cells exhibit effective antitumour activity in vitro and in mouse models. Therefore, by achieving programmable and site-specific kilobase-scale DNA insertions&#xa0;without&#xa0;double-strand breaks while reducing unintended outcomes, KNIT editing provides a versatile platform for advancing personalized medicine.

Animals

Validating the splicing effect of rare variants in the SLC26A4 gene using minigene assay.

BACKGROUND: The SLC26A4 gene is the second most common cause of hereditary hearing loss in human. The aim of this study was to utilize the minigene assay in order to identify pathogenic variants of SLC26A4 associated with enlarged vestibular aqueduct (EVA) and hearing loss (HL) in two patients. METHODS: The patients were subjected to multiplex PCR amplification and next-generation sequencing of common deafness genes (including GJB2, SLC26A4, and MT-RNR1), then bioinformatics analysis was performed on the sequencing data to identify candidate pathogenic variants. Minigene experiments were conducted to determine the potential impact of the variants on splicing. RESULTS: Genetic testing revealed that the first patient carried compound heterozygous variants c.[1149&#x2009;+&#x2009;1G&#x2009;>&#x2009;A]; [919-2&#xa0;A&#x2009;>&#x2009;G] in the SLC26A4 gene, while the second patient carried compound heterozygous variants c.[2089&#x2009;+&#x2009;3&#xa0;A&#x2009;>&#x2009;T]; [919-2&#xa0;A&#x2009;>&#x2009;G] in the same gene. Minigene experiments demonstrated that both c.1149&#x2009;+&#x2009;1G&#x2009;>&#x2009;A and c.2089&#x2009;+&#x2009;3&#xa0;A&#x2009;>&#x2009;T affected mRNA splicing. According to the ACMG guidelines and the recommendations of the ClinGen Hearing Loss Expert Panel for ACMG variant interpretation, these variants were classified as "likely pathogenic". CONCLUSIONS: This study identified the molecular etiology of hearing loss in two patients with EVA and elucidated the impact of rare variants on splicing, thus contributing to the mutational spectrum of pathogenic variants in the SLC26A4 gene.

Humans